MXPA05007831A - Preparacion de quinazolinas substituidas. - Google Patents

Preparacion de quinazolinas substituidas.

Info

Publication number
MXPA05007831A
MXPA05007831A MXPA05007831A MXPA05007831A MXPA05007831A MX PA05007831 A MXPA05007831 A MX PA05007831A MX PA05007831 A MXPA05007831 A MX PA05007831A MX PA05007831 A MXPA05007831 A MX PA05007831A MX PA05007831 A MXPA05007831 A MX PA05007831A
Authority
MX
Mexico
Prior art keywords
preparation
disclosed
inhibitors
substituted quinazolines
methods
Prior art date
Application number
MXPA05007831A
Other languages
English (en)
Inventor
Elliott Jacks Thomas
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MXPA05007831A publication Critical patent/MXPA05007831A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describen metodos y materiales para la preparacion de inhibidores irreversibles de tirosina quinasas de Formula general 1. Dichos Inhibidores, que incluyen N-[4 -(3- cloro- 4-fluoro- fenilamino)- 7-(3-morfolin -4-il- propoxi)- quinazolin -6-il] -acrilamida, son utiles para el tratamiento del cancer, restenosis, ateroesclerosis, endometriosis y psoriasis. Los metodos descritos emplean estrategias protectoras para minimizar productos laterales diacriloilamino-quinazolina indeseables. (ver formula 1).
MXPA05007831A 2003-02-05 2004-02-03 Preparacion de quinazolinas substituidas. MXPA05007831A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44509503P 2003-02-05 2003-02-05
PCT/IB2004/000321 WO2004069791A2 (en) 2003-02-05 2004-02-03 Preparation of substituted quinazolines

Publications (1)

Publication Number Publication Date
MXPA05007831A true MXPA05007831A (es) 2005-10-18

Family

ID=32850969

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05007831A MXPA05007831A (es) 2003-02-05 2004-02-03 Preparacion de quinazolinas substituidas.

Country Status (18)

Country Link
US (1) US20040158065A1 (es)
EP (1) EP1618095A2 (es)
JP (1) JP2006517959A (es)
KR (1) KR20050095916A (es)
CN (1) CN1745073A (es)
AR (1) AR043027A1 (es)
AU (1) AU2004209452A1 (es)
BR (1) BRPI0407249A (es)
CA (1) CA2514933A1 (es)
MX (1) MXPA05007831A (es)
NL (3) NL1025414C2 (es)
PA (1) PA8595201A1 (es)
PE (1) PE20040945A1 (es)
PL (1) PL378576A1 (es)
RU (1) RU2005122322A (es)
TW (1) TW200420544A (es)
UY (1) UY28177A1 (es)
WO (1) WO2004069791A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078735A1 (de) 1999-06-21 2000-12-28 Boehringer Ingelheim Pharma Kg Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
KR101028952B1 (ko) * 2003-08-14 2011-04-12 어레이 바이오파마 인크. 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
DE10349113A1 (de) * 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
ME01267B (me) * 2004-05-06 2013-06-20 Warner Lambert Co 4-fenilaminokinazolin-6-ilamidi
KR100735639B1 (ko) * 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
KR100832593B1 (ko) * 2005-11-08 2008-05-27 한미약품 주식회사 신호전달 저해제로서의 퀴나졸린 유도체 및 이의 제조방법
WO2007054550A1 (en) 2005-11-11 2007-05-18 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
CA2632194C (en) 2005-11-15 2012-01-03 Array Biopharma Inc. N4-phenyl-quinazoline-4-amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
KR20090074202A (ko) * 2006-09-18 2009-07-06 베링거 인겔하임 인터내셔날 게엠베하 Ｅｇｆｒ 돌연변이를 갖는 암을 치료하는 방법
CA2698944C (en) * 2007-09-10 2015-06-16 Curis, Inc. Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety
US8609673B2 (en) * 2008-01-22 2013-12-17 Concert Pharmaceuticals, Inc. Vandetanib derivatives
WO2009094216A1 (en) * 2008-01-22 2009-07-30 Concert Pharmaceuticals Inc. Derivatives of gefitinib
KR101341876B1 (ko) * 2008-09-05 2013-12-20 셀진 아빌로믹스 리서치, 인코포레이티드 비가역 인히비터 디자인을 위한 알고리즘
WO2011003853A2 (en) 2009-07-06 2011-01-13 Boehringer Ingelheim International Gmbh Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
AU2010295690B2 (en) 2009-09-16 2016-07-28 Celgene Avilomics Research, Inc. Protein kinase conjugates and inhibitors
SG181965A1 (en) 2009-12-30 2012-08-30 Avila Therapeutics Inc Ligand-directed covalent modification of protein
CN102382106A (zh) * 2010-08-30 2012-03-21 黄振华 苯胺取代的喹唑啉衍生物
US9371292B2 (en) 2011-07-27 2016-06-21 Shanghai Pharmaceuticals Holdings Co., Ltd. Quinazoline derivative, preparation method therefor, intermediate, composition and application thereof
KR20140093223A (ko) * 2011-10-12 2014-07-25 텔리진 엘티디. 키나제 억제제로서의 퀴나졸린 유도체 및 이의 사용 방법
KR20150005698A (ko) 2012-05-07 2015-01-14 텔리진 엘티디. 키나제 저해제로서 유용한 치환된 아미노퀴나졸린
CN103965120B (zh) * 2013-01-25 2016-08-17 上海医药集团股份有限公司 喹啉及喹唑啉衍生物、制备方法、中间体、组合物及应用
CN103242244B (zh) * 2013-05-16 2015-03-25 苏州明锐医药科技有限公司 一种卡奈替尼的制备方法
US9694011B2 (en) 2013-05-21 2017-07-04 Jiangsu Medolution Ltd Substituted pyrazolopyrimidines as kinases inhibitors
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
US10870627B2 (en) 2016-09-23 2020-12-22 Shanghai Pharmaceuticals Holding Co., Ltd. Salt of quinazoline derivative, preparation method therefor and application thereof
TW202413336A (zh) 2018-03-08 2024-04-01 美商英塞特公司 作為PI3K-γ抑制劑之胺基吡嗪二醇化合物
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
EP3856726A1 (en) 2018-09-25 2021-08-04 Black Diamond Therapeutics, Inc. Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
AU2020231822A1 (en) * 2019-03-07 2021-08-26 BioNTech SE Process for the preparation of a substituted imidazoquinoline
KR20220147021A (ko) * 2021-04-22 2022-11-02 보로노이 주식회사 헤테로아릴 유도체 화합물 및 이의 용도
WO2023044364A1 (en) 2021-09-15 2023-03-23 Enko Chem, Inc. Protoporphyrinogen oxidase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE213730T1 (de) * 1996-04-12 2002-03-15 Warner Lambert Co Umkehrbare inhibitoren von tyrosin kinasen
US6664390B2 (en) * 2000-02-02 2003-12-16 Warner-Lambert Company Llc Method for the simplified production of (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazoline-4-yl]-amine or (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazoline-4-yl]-amine
DE10009267A1 (de) * 2000-02-26 2001-08-30 Goedecke Ag Verfahren zur einfachen Herstellung von (3-Chlor-4-fluor-phenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazolin-4-yl]-amin bzw. (3-Chlor-4-fluor-phenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazolin-4-yl]-amin
US6627634B2 (en) * 2000-04-08 2003-09-30 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
DE10063435A1 (de) * 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
UY28177A1 (es) 2004-09-30
NL1029763A1 (nl) 2005-10-13
PA8595201A1 (es) 2004-09-16
AU2004209452A1 (en) 2004-08-19
US20040158065A1 (en) 2004-08-12
CA2514933A1 (en) 2004-08-19
NL1029762A1 (nl) 2005-10-13
JP2006517959A (ja) 2006-08-03
AR043027A1 (es) 2005-07-13
CN1745073A (zh) 2006-03-08
BRPI0407249A (pt) 2006-01-31
NL1025414A1 (nl) 2004-08-06
NL1029762C2 (nl) 2006-03-06
RU2005122322A (ru) 2006-03-10
WO2004069791A2 (en) 2004-08-19
NL1025414C2 (nl) 2005-11-01
NL1029763C2 (nl) 2006-03-06
KR20050095916A (ko) 2005-10-04
WO2004069791A3 (en) 2004-12-16
EP1618095A2 (en) 2006-01-25
PL378576A1 (pl) 2006-05-02
PE20040945A1 (es) 2004-12-14
TW200420544A (en) 2004-10-16

Similar Documents

Publication Publication Date Title
MXPA05007831A (es) Preparacion de quinazolinas substituidas.
HUP0104211A2 (hu) Tirozin-kinázok irreverzibilis inhibitoraként ható N-[4-(4-fluor-3-klór-anilino)-7-(3-morfolino-propoxi)-6-kinazolinil]-akrilamid és a vegyületet tartalmazó gyógyszerkészítmény
IL173348A0 (en) Thienopyridine and furopyridine kinase inhibitors
MX2009002585A (es) Inhibidores e egfr a base de quinolina que contienen porcion de enlace de zinc.
HK1068886A1 (en) Indolinone derivatives useful as protein kinase inhibitors
HK1076598A1 (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
YU66100A (sh) N-(3-etinilfenilamino)-6,7-bis(2-metoksietoksi)-4- hinazolinamin mezilat, bezvodni i monohidrat
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
WO2004031401A3 (en) Novel tyrosine kinases inhibitors
WO2006050109A3 (en) Novel kinase inhibitors
UA85394C2 (ru) Замещенные хинолины в качестве ингибиторов ферментов протеинтирозиновых киназ
ATE343575T1 (de) Azaoxoindol derivate als trk protein kinase hemmstoffe zur behandlung von krebs und chronischem schmerz
HK1079195A1 (en) Quinazoline derivatives as src tyrosine kinase inhibitors
MXPA05013076A (es) Compuestos de isoindolina-1-ona como inhibidores de cinasa.
WO2004092144A3 (en) Quinazoline compounds useful as p38 kinase inhibitors
MXPA06003161A (es) Derivados de quinazolina.
WO2004013091A3 (en) 4-anilido substituted quinazolines and use thereof as inhibitors of epidermal growth factor receptor kinases
AP2002002694A0 (en) Polymorphic forms/hydrates of n-[4-(3-chloro-4-fluorophenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide dihydrochloride.
DOP2004000812A (es) Preparacion de quinazolinas substituidas